{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T18:05:03Z","timestamp":1760551503165,"version":"build-2065373602"},"reference-count":98,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jfma.2021.06.014","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T04:21:29Z","timestamp":1625631689000},"page":"1941-1948","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Advances in antigens associated with Idiopathic Membranous Nephropathy"],"prefix":"10.1016","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1029-8405","authenticated-orcid":false,"given":"Shan-Shan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-E","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6840-9158","authenticated-orcid":false,"given":"Yong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2021.06.014_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00467-013-2717-z","article-title":"Membranous nephropathy: not just a disease for adults","volume":"30","author":"Ayalon","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.jfma.2021.06.014_bib2","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/S0140-6736(15)60731-0","article-title":"Pathophysiological advances in membranous nephropathy: time for a shift in patient's care","volume":"385","author":"Ronco","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2021.06.014_bib3","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2215\/CJN.04160413","article-title":"Glomerular diseases: membranous nephropathy-a modern view","volume":"9","author":"Ponticelli","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2021.06.014_bib4","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jfma.2014.11.002","article-title":"Membranous nephropathy: a review on the pathogenesis, diagnosis, and treatment","volume":"114","author":"Lai","year":"2015","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2021.06.014_bib5","first-page":"139","article-title":"KDIGO clinical practice guideline for glomerulonephritis","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.jfma.2021.06.014_bib6","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/j.ajkd.2016.01.030","article-title":"Membranous nephropathy: a journey from bench to bedside","volume":"68","author":"Francis","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jfma.2021.06.014_bib7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1053\/j.ajkd.2010.01.008","article-title":"The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey","volume":"56","author":"Glassock","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jfma.2021.06.014_bib8","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2215\/CJN.11761116","article-title":"Primary membranous nephropathy","volume":"12","author":"Couser","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2021.06.014_bib9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/cei.12729","article-title":"Immunology of membranous nephropathy: from animal models to humans","volume":"183","author":"Sinico","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jfma.2021.06.014_bib10","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1681\/ASN.2016070776","article-title":"A proposal for a serology-based approach to membranous nephropathy","volume":"28","author":"De Vriese","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2021.06.014_bib11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrneph.2012.35","article-title":"Pathogenesis of membranous nephropathy: recent advances and future challenges","volume":"8","author":"Ronco","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jfma.2021.06.014_bib12","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/ndt\/gfq665","article-title":"The incidence of primary glomerulonephritis worldwide: a systematic review of the literature","volume":"26","author":"McGrogan","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jfma.2021.06.014_bib13","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1093\/ndt\/gfh521","article-title":"The Czech registry of renal biopsies. Occurrence of renal diseases in the years 1994-2000","volume":"19","author":"Rychlik","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jfma.2021.06.014_bib14","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0270-9295(03)00049-4","article-title":"Diagnosis and natural course of membranous nephropathy","volume":"23","author":"Glassock","year":"2003","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.jfma.2021.06.014_bib15","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1681\/ASN.2009080861","article-title":"Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy","volume":"21","author":"Polanco","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2021.06.014_bib16","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.3389\/fimmu.2019.01809","article-title":"Immunological pathogenesis of membranous nephropathy: focus on PLA2R1 and its role","volume":"10","author":"Liu","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jfma.2021.06.014_bib17","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1056\/NEJMoa012895","article-title":"Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies","volume":"346","author":"Debiec","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2021.06.014_bib18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2021.06.014_bib19","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2021.06.014_bib20","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.kint.2019.09.014","article-title":"Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy","volume":"97","author":"Sethi","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.jfma.2021.06.014_bib21","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1007\/s00018-007-7497-9","article-title":"Extended and bent conformations of the mannose receptor family","volume":"65","author":"Llorca","year":"2008","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jfma.2021.06.014_bib22","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0165-6147(99)01300-0","article-title":"Receptors for a growing family of secreted phospholipases A2","volume":"20","author":"Lambeau","year":"1999","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jfma.2021.06.014_bib23","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1681\/ASN.2009121220","article-title":"Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy","volume":"21","author":"Ronco","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2021.06.014_bib24","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.kint.2019.10.022","article-title":"A novel mouse model of phospholipase A2 receptor 1-associated membranous nephropathy mimics podocyte injury in patients","volume":"97","author":"Meyer-Schwesinger","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.jfma.2021.06.014_bib25","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1681\/ASN.2013121315","article-title":"Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy","volume":"26","author":"Kao","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2021.06.014_bib26","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2014050502","article-title":"Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy","volume":"26","author":"Fresquet","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2021.06.014_bib27","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1681\/ASN.2014111061","article-title":"Epitope spreading of autoantibody response to PLA2R associates with poor prognosis in membranous nephropathy","volume":"27","author":"Seitz-Polski","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2021.06.014_bib28","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1681\/ASN.2017070734","article-title":"Phospholipase A2 receptor 1 epitope spreading at baseline predicts reduced likelihood of remission of membranous nephropathy","volume":"29","author":"Seitz-Polski","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2021.06.014_bib29","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1009742","article-title":"Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy","volume":"364","author":"Stanescu","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2021.06.014_bib30","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2215\/CJN.05310513","article-title":"HLA-DQA1 and PLA2R1 polymorphisms and risk of idiopathic membranous nephropathy","volume":"9","author":"Bullich","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2021.06.014_bib31","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1093\/ndt\/gfv399","article-title":"PLA2R antibodies, glomerular PLA2R deposits and variations in PLA2R1 and HLA-DQA1 genes in primary membranous nephropathy in South Asians","volume":"31","author":"Ramachandran","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jfma.2021.06.014_bib32","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1681\/ASN.2012080771","article-title":"Interaction between PLA2R1 and HLA-DQA1 variants associates with anti-PLA2R antibodies and membranous nephropathy","volume":"24","author":"Lv","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2021.06.014_bib33","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1681\/ASN.2012070730","article-title":"Phospholipase A2 receptor (PLA2R1) sequence variants in idiopathic membranous nephropathy","volume":"24","author":"Coenen","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2021.06.014_bib34","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.2215\/CJN.07210810","article-title":"Anti-phospholipase A(2) receptor antibodies correlate with clinical status in idiopathic membranous nephropathy","volume":"6","author":"Hofstra","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2021.06.014_bib35","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1681\/ASN.2015080953","article-title":"Combined assessment of phospholipase A2 receptor autoantibodies and glomerular deposits in membranous nephropathy","volume":"27","author":"Qin","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2021.06.014_bib36","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3389\/fmed.2018.00101","article-title":"Diagnostic test accuracy of serum anti-PLA2R autoantibodies and glomerular PLA2R antigen for diagnosing idiopathic membranous nephropathy: an updated meta-analysis","volume":"5","author":"Li","year":"2018","journal-title":"Front Med"},{"key":"10.1016\/j.jfma.2021.06.014_bib37","doi-asserted-by":"crossref","first-page":"143274","DOI":"10.1155\/2014\/143274","article-title":"Antiphospholipase A(2) receptor autoantibodies: a comparison of three different immunoassays for the diagnosis of idiopathic membranous nephropathy","volume":"2014","author":"Behnert","year":"2014","journal-title":"J Immunol Res"},{"key":"10.1016\/j.jfma.2021.06.014_bib38","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1681\/ASN.2013040430","article-title":"Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy","volume":"25","author":"Hoxha","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2021.06.014_bib39","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/ki.2012.486","article-title":"Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy","volume":"83","author":"Kanigicherla","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.jfma.2021.06.014_bib40","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/sj.ki.5002628","article-title":"Rituximab treatment of idiopathic membranous nephropathy","volume":"73","author":"Fervenza","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.jfma.2021.06.014_bib41","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.2215\/CJN.05080610","article-title":"Rituximab therapy in idiopathic membranous nephropathy: a 2-year study","volume":"5","author":"Fervenza","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2021.06.014_bib42","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1681\/ASN.2012020181","article-title":"Rituximab in idiopathic membranous nephropathy","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2021.06.014_bib43","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrneph.2017.92","article-title":"Treatment of membranous nephropathy: time for a paradigm shift","volume":"13","author":"Ruggenenti","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jfma.2021.06.014_bib44","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1681\/ASN.2010111125","article-title":"Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy","volume":"22","author":"Beck","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2021.06.014_bib45","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2021.06.014_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104936","article-title":"The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: a meta-analysis","volume":"9","author":"Du","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.jfma.2021.06.014_bib47","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.2215\/CJN.01460217","article-title":"Circulating antibodies against thrombospondin type-I domain-containing 7A in Chinese patients with idiopathic membranous nephropathy","volume":"12","author":"Wang","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2021.06.014_bib48","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s11255-019-02146-w","article-title":"Circulating antibodies against M-type phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A in Chinese patients with membranous nephropathy","volume":"51","author":"Tian","year":"2019","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.jfma.2021.06.014_bib49","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/jcp.21990","article-title":"Thrombospondin type I domain containing 7A (THSD7A) mediates endothelial cell migration and tube formation","volume":"222","author":"Wang","year":"2010","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.jfma.2021.06.014_bib50","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1681\/ASN.2018090941","article-title":"Thrombospondin type 1 domain-containing 7A localizes to the slit diaphragm and stabilizes membrane dynamics of fully differentiated podocytes","volume":"30","author":"Herwig","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2021.06.014_bib51","first-page":"1074","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"372","author":"Meyer-Schwesinger","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2021.06.014_bib52","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1681\/ASN.2017070805","article-title":"The most N-terminal region of THSD7A is the predominant target for autoimmunity in THSD7A-associated membranous nephropathy","volume":"29","author":"Seifert","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2021.06.014_bib53","doi-asserted-by":"crossref","first-page":"102308","DOI":"10.1016\/j.jaut.2019.102308","article-title":"Autoantigens PLA2R and THSD7A in membranous nephropathy share a common epitope motif in the N-terminal domain","volume":"106","author":"Fresquet","year":"2020","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jfma.2021.06.014_bib54","first-page":"5076","article-title":"Clinical and histological features of phospholipase A2 receptor-associated and thrombospondin type-I domain-containing 7A-associated idiopathic membranous nephropathy: a single center retrospective study from China","volume":"24","author":"Zhang","year":"2018","journal-title":"Med Sci Mon Int Med J Exp Clin Res"},{"key":"10.1016\/j.jfma.2021.06.014_bib55","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1681\/ASN.2016010050","article-title":"An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7A-specific antibodies in membranous nephropathy","volume":"28","author":"Hoxha","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2021.06.014_bib56","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/modpathol.2016.32","article-title":"THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity","volume":"29","author":"Larsen","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jfma.2021.06.014_bib57","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1172\/JCI85265","article-title":"Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy","volume":"126","author":"Tomas","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jfma.2021.06.014_bib58","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1681\/ASN.2017010030","article-title":"A heterologous model of thrombospondin type 1 domain-containing 7A-associated membranous nephropathy","volume":"28","author":"Tomas","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2021.06.014_bib59","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.kint.2018.10.024","article-title":"Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy","volume":"95","author":"Zaghrini","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.jfma.2021.06.014_bib60","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/gcc.22440","article-title":"THSD7A expression in human cancer","volume":"56","author":"Stahl","year":"2017","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.jfma.2021.06.014_bib61","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1136\/jclinpath-2019-205852","article-title":"Features of phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A in malignancy-associated membranous nephropathy","volume":"72","author":"Zhang","year":"2019","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jfma.2021.06.014_bib62","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMc1511702","article-title":"A mechanism for cancer-associated membranous nephropathy","volume":"374","author":"Hoxha","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2021.06.014_bib63","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1177\/0022034510376401","article-title":"The role of NELL-1, a growth factor associated with craniosynostosis, in promoting bone regeneration","volume":"89","author":"Zhang","year":"2010","journal-title":"J Dent Res"},{"key":"10.1016\/j.jfma.2021.06.014_bib64","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1016\/j.febslet.2012.06.014","article-title":"The C-terminal region of NELL1 mediates osteoblastic cell adhesion through integrin alpha3beta1","volume":"586","author":"Hasebe","year":"2012","journal-title":"FEBS Lett"},{"key":"10.1016\/j.jfma.2021.06.014_bib65","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1006\/geno.1996.0628","article-title":"Cloning and characterization of two novel human cDNAs (NELL1 and NELL2) encoding proteins with six EGF-like repeats","volume":"38","author":"Watanabe","year":"1996","journal-title":"Genomics"},{"key":"10.1016\/j.jfma.2021.06.014_bib66","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/cas.12649","article-title":"Expression and regulatory effects on cancer cell behavior of NELL1 and NELL2 in human renal cell carcinoma","volume":"106","author":"Nakamura","year":"2015","journal-title":"Canc Sci"},{"key":"10.1016\/j.jfma.2021.06.014_bib67","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.kint.2020.07.039","article-title":"NELL1 is a target antigen in malignancy-associated membranous nephropathy","volume":"99","author":"Caza","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.jfma.2021.06.014_bib68","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1093\/ndt\/gfr534","article-title":"Absence of glomerular IgG4 deposition in patients with membranous nephropathy may indicate malignancy","volume":"27","author":"Qu","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jfma.2021.06.014_bib69","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.kint.2019.10.009","article-title":"Antigens, antibodies, and membranous nephropathy: a decade of progress","volume":"97","author":"Ahmad","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.jfma.2021.06.014_bib70","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.kint.2020.05.030","article-title":"Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients","volume":"98","author":"Sethi","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.jfma.2021.06.014_bib71","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ni1553","article-title":"Semaphorins and their receptors in immune cell interactions","volume":"9","author":"Suzuki","year":"2008","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jfma.2021.06.014_bib72","doi-asserted-by":"crossref","first-page":"6922","DOI":"10.1158\/0008-5472.CAN-07-5408","article-title":"Semaphorin-3B is an angiogenesis inhibitor that is inactivated by furin-like pro-protein convertases","volume":"68","author":"Varshavsky","year":"2008","journal-title":"Canc Res"},{"key":"10.1016\/j.jfma.2021.06.014_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2016.08.001","article-title":"The semaphorins and their receptors as modulators of tumor progression","volume":"29","author":"Neufeld","year":"2016","journal-title":"Drug Resist Updates"},{"key":"10.1016\/j.jfma.2021.06.014_bib74","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrd4337","article-title":"Semaphorins and plexins as therapeutic targets","volume":"13","author":"Worzfeld","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jfma.2021.06.014_bib75","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/joim.12017","article-title":"Class 3 semaphorins: physiological vascular normalizing agents for anti-cancer therapy","volume":"273","author":"Serini","year":"2013","journal-title":"J Intern Med"},{"key":"10.1016\/j.jfma.2021.06.014_bib76","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/nrc2404","article-title":"The semaphorins: versatile regulators of tumour progression and tumour angiogenesis","volume":"8","author":"Neufeld","year":"2008","journal-title":"Nat Rev Canc"},{"key":"10.1016\/j.jfma.2021.06.014_bib77","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.1158\/1078-0432.CCR-09-1810","article-title":"Role of class 3 semaphorins and their receptors in tumor growth and angiogenesis","volume":"15","author":"Gaur","year":"2009","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.jfma.2021.06.014_bib78","doi-asserted-by":"crossref","first-page":"11432","DOI":"10.1073\/pnas.0403969101","article-title":"Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect","volume":"101","author":"Castro-Rivera","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jfma.2021.06.014_bib79","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1084\/jem.20072509","article-title":"The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment","volume":"205","author":"Rolny","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/j.jfma.2021.06.014_bib80","doi-asserted-by":"crossref","first-page":"8295","DOI":"10.1158\/0008-5472.CAN-07-6601","article-title":"Semaphorin 3B inhibits the phosphatidylinositol 3-kinase\/Akt pathway through neuropilin-1 in lung and breast cancer cells","volume":"68","author":"Castro-Rivera","year":"2008","journal-title":"Canc Res"},{"key":"10.1016\/j.jfma.2021.06.014_bib81","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1158\/1535-7163.MCT-09-0664","article-title":"Hormonal regulation and distinct functions of semaphorin-3B and semaphorin-3F in ovarian cancer","volume":"9","author":"Joseph","year":"2010","journal-title":"Mol Canc Therapeut"},{"key":"10.1016\/j.jfma.2021.06.014_bib82","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1158\/1541-7786.MCR-11-0213","article-title":"Progesterone and 1,25-dihydroxyvitamin D(3) inhibit endometrial cancer cell growth by upregulating semaphorin 3B and semaphorin 3F","volume":"9","author":"Nguyen","year":"2011","journal-title":"Mol Canc Res"},{"key":"10.1016\/j.jfma.2021.06.014_bib83","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1681\/ASN.2008121259","article-title":"Autoimmunity in membranous nephropathy targets aldose reductase and SOD2","volume":"21","author":"Prunotto","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2021.06.014_bib84","first-page":"447","article-title":"Localization of the polyol pathway in the human kidney","volume":"24","author":"Zopf","year":"2009","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.jfma.2021.06.014_bib85","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1210\/er.2004-0028","article-title":"Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options","volume":"26","author":"Srivastava","year":"2005","journal-title":"Endocr Rev"},{"key":"10.1016\/j.jfma.2021.06.014_bib86","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ki.2010.141","article-title":"Protective role of extracellular superoxide dismutase in renal ischemia\/reperfusion injury","volume":"78","author":"Schneider","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.jfma.2021.06.014_bib87","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00281-014-0423-y","article-title":"Immunopathogenesis of membranous nephropathy: an update","volume":"36","author":"Debiec","year":"2014","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jfma.2021.06.014_bib88","first-page":"1825","article-title":"Clinical significance of autoantibodies in the assessment and treatment of idiopathic membranous nephropathy","volume":"17","author":"Han","year":"2019","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.jfma.2021.06.014_bib89","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1365-2249.1999.01080.x","article-title":"Circulating antibodies against alpha-enolase in patients with primary membranous nephropathy (MN)","volume":"118","author":"Wakui","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jfma.2021.06.014_bib90","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.jprot.2011.05.021","article-title":"Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: alfa-enolase and borderline antigens","volume":"74","author":"Bruschi","year":"2011","journal-title":"J Proteomics"},{"key":"10.1016\/j.jfma.2021.06.014_bib91","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1007\/PL00000910","article-title":"Multifunctional alpha-enolase: its role in diseases","volume":"58","author":"Pancholi","year":"2001","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jfma.2021.06.014_bib92","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1006\/clin.1996.0021","article-title":"The occurrence of serum autoantibodies against enolase in cancer-associated retinopathy","volume":"78","author":"Adamus","year":"1996","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.jfma.2021.06.014_bib93","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1006\/jaut.1998.0239","article-title":"Anti-enolase-alpha autoantibodies in cancer-associated retinopathy: epitope mapping and cytotoxicity on retinal cells","volume":"11","author":"Adamus","year":"1998","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jfma.2021.06.014_bib94","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1681\/ASN.2013090987","article-title":"Glomerular autoimmune multicomponents of human lupus nephritis in\u00a0vivo: alpha-enolase and annexin AI","volume":"25","author":"Bruschi","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2021.06.014_bib95","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/ki.1993.97","article-title":"Alpha-enolase: a novel cytosolic autoantigen in ANCA positive vasculitis","volume":"43","author":"Moodie","year":"1993","journal-title":"Kidney Int"},{"key":"10.1016\/j.jfma.2021.06.014_bib96","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.2215\/CJN.02170312","article-title":"Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy","volume":"7","author":"Murtas","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jfma.2021.06.014_bib97","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0048845","article-title":"Identification and characterization of a new autoimmune protein in membranous nephropathy by immunoscreening of a renal cDNA library","volume":"7","author":"Cavazzini","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.jfma.2021.06.014_bib98","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1681\/ASN.2012090913","article-title":"Nephrotic syndrome caused by immune-mediated acquired LCAT deficiency","volume":"24","author":"Takahashi","year":"2013","journal-title":"J Am Soc Nephrol"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664621002941?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664621002941?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:46:06Z","timestamp":1760539566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664621002941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":98,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0929664621002941"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2021.06.014","relation":{},"ISSN":["0929-6646"],"issn-type":[{"type":"print","value":"0929-6646"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in antigens associated with Idiopathic Membranous Nephropathy","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2021.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}